fluorobenzenes has been researched along with Kidney Failure, Chronic in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 18 (78.26) | 29.6817 |
2010's | 5 (21.74) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Azumaya, C; Birmingham, BK; Mitchell, P; Puchalski, T; Swan, SK; Wang, Y; Zalikowski, J | 1 |
Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
Nitta, K; Ogawa, T; Sawara, Y; Takei, T; Tsuchiya, K; Uchida, K; Yoshida, T | 1 |
Craig, JC; Strippoli, GF | 1 |
Bannister, K; Beutler, J; Chae, DW; Chevaile, A; Cobbe, SM; De Lima, JJ; Fellström, BC; Gottlow, M; Grönhagen-Riska, C; Holdaas, H; Jardine, AG; Johnsson, E; Lins, R; Mayer, G; McMahon, AW; Parving, HH; Remuzzi, G; Samuelsson, O; Schmieder, RE; Sci, D; Sonkodi, S; Süleymanlar, G; Tesar, V; Todorov, V; Tsakiris, D; Wiecek, A; Wüthrich, RP; Zannad, F | 1 |
Fabbri, G; Maggioni, AP | 1 |
Ganguli, A | 1 |
Ruilope, LM; Segura, J | 1 |
Kassimatis, TI; Konstantinopoulos, PA | 1 |
de Oliveira, JM | 1 |
Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K | 1 |
Aguilar, EA; Ebenezer, PJ; Francis, J; Hu, X; Larroque, M; Lee, BS; Liao, J; Morse, SA; Reisin, E | 1 |
Barrios, V; Escobar, C | 1 |
Bologa, R; Cheigh, J; Gordon, B; Lanto, A; Levine, D; Parker, T; Rubin, A; Stenzel, K | 1 |
Macias, JF; Robles, NR | 1 |
Fellström, BC; Holdaas, H; Holme, I; Jardine, AG; Norby, GE; Schmieder, RE; Zannad, F | 1 |
Abe, M; Ito, M; Maruyama, N; Okada, K; Soma, M; Yoshida, Y | 1 |
Krane, V; Wanner, C | 1 |
Fellström, BC; Holdaas, H; Jardine, AG | 1 |
Davidson, M | 1 |
Gordon, NF; Ranganna, KM; Reddy, RS; Verma, A; Verma, M | 1 |
Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
Fellström, B; Holdaas, H; Jardine, AG; Rose, H; Schmieder, R; Wilpshaar, W; Zannad, F | 1 |
7 review(s) available for fluorobenzenes and Kidney Failure, Chronic
Article | Year |
---|---|
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Evidence-Based Medicine; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Kidney Failure, Chronic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.
Topics: Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2009 |
Cardiovascular risk in uremic patients: darkness after AURORA.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Patient Dropouts; Patient Selection; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Risk; Rosuvastatin Calcium; Sulfonamides; Uremia | 2010 |
Why do we need a statin trial in hemodialysis patients?
Topics: Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Uremia | 2003 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
7 trial(s) available for fluorobenzenes and Kidney Failure, Chronic
Article | Year |
---|---|
Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima | 2008 |
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides; Treatment Failure | 2009 |
Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.
Topics: Chromatography, High Pressure Liquid; Dyslipidemias; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin in diabetic hemodialysis patients.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Diabetes Complications; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides | 2011 |
Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
Topics: Aged; Blood Glucose; Blood Pressure; Cytoprotection; Diabetic Nephropathies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease.
Topics: Aged; Biomarkers; C-Reactive Protein; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Lipoproteins, LDL; Male; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Fluorobenzenes; Humans; Internationality; Kidney Failure, Chronic; Male; Middle Aged; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
9 other study(ies) available for fluorobenzenes and Kidney Failure, Chronic
Article | Year |
---|---|
Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.
Topics: Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides | 2013 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Sunset for statins after AURORA?
Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides; Treatment Failure | 2009 |
Rosuvastatin in patients undergoing hemodialysis.
Topics: Cardiovascular Diseases; Confounding Factors, Epidemiologic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperphosphatemia; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Phosphorus; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Research Design; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin in patients undergoing hemodialysis.
Topics: Cardiovascular Diseases; Diabetes Complications; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients undergoing hemodialysis.
Topics: Age Factors; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Pyrimidines; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet.
Topics: Animals; Base Sequence; Blood Pressure; C-Reactive Protein; Dietary Fats; DNA Primers; Feeding Behavior; Fluorescent Antibody Technique; Fluorobenzenes; Gene Expression Profiling; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Kidney Failure, Chronic; Lipids; Pyrimidines; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2009 |
Sunrise of statins after AURORA and 4D?
Topics: Diabetes Complications; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |